Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

ACAD - ACADIA Pharmaceuticals Inc. So'nggi... | Finranks

Home

/

ACAD

A

ACADIA Pharmaceuticals Inc. (ACAD)

NMS – Real vaqt narxi. Valyuta: USD

29.70

+0.29 (0.99%)

Bozor ochiq: Aug 12, 2026, 1:08 PM EDT

29.99

+0.58 (1.97%)

Oldingi bozordan keyin: Aug 11, 2026, 7:39 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.16 per share a year ago.

ACADIA Pharmaceuticals Q2 Earnings Call Highlights

ACADIA Pharmaceuticals Q2 Earnings Call Highlights

ACADIA Pharmaceuticals NASDAQ: ACAD reported second-quarter 2026 revenue of $308 million, representing 17% year-over-year growth on an adjusted basis, as sales of its Rett syndrome therapy DAYBUE and Parkinson's disease psychosis treatment NUPLAZID increased.

Videolar

No Data

There is no data to display

Press-relizlar

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026. “Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued patient demand and robust uptake of STIX drove another q.